

# Depression in patients with knee osteoarthritis: risk factors and associations with joint symptoms

**Shuang Zheng**

University of Tasmania <https://orcid.org/0000-0003-3552-1247>

**Liudan Tu**

Third Affiliated Hospital of SUN YAT-SEN University

**Flavia Cicuttini**

Monash University

**Zhaohua Zhu**

Zhujiang Hospital, Southern Medical University

**Weiyu Han**

Zhujiang Hospital, Southern Medical University

**Benny Antony**

Menzies Institute for Medical Research, University of Tasmania

**Anita E. Wluka**

Monash University

**Tania Winzenberg**

Menzies Institute for Medical Research

**Dawn Aitken**

Menzies Institute for Medical Research, University of Tasmania

**Leigh Blizzard**

Menzies Institute for Medical Research, University of Tasmania

**Graeme Jones**

Menzies Institute for Medical Research, University of Tasmania

**Changhai Ding** (✉ [changhai.ding@utas.edu.au](mailto:changhai.ding@utas.edu.au))

---

## Research article

**Keywords:** Depression, knee osteoarthritis, risk factors, joint symptoms

**Posted Date:** May 31st, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-31807/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on January 7th, 2021. See the published version at <https://doi.org/10.1186/s12891-020-03875-1>.

# Abstract

## Background

To describe demographic and clinical factors associated with the prevalence and incidence of depression and explore the temporal relationship between depression and joint symptoms in patients with symptomatic knee osteoarthritis (OA).

## Methods

413 participants were selected from a randomized controlled trial in people with symptomatic knee OA and vitamin D deficiency (age  $63.2 \pm 7.0$  year, 50.4% female). Depression severity and knee joint symptoms were assessed using the patient health questionnaire (PHQ-9) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), respectively, at baseline and 24 months.

## Results

The prevalence and incidence of depression was 25.4% and 11.2%, respectively. At baseline, having a higher body mass index (BMI), greater scores of WOMAC pain (PR: 1.05, 95%CI:1.03, 1.07), dysfunction (PR: 1.02, 95%CI:1.01, 1.02) and stiffness (PR: 1.05, 95%CI: 1.02, 1.09), lower education level, having more than one comorbidity and having two or more painful body sites were significantly associated with a higher prevalence of depression. Over 24 months, being female, having a higher WOMAC pain (RR: 1.04, 95%CI: 1.00, 1.08) and dysfunction score (RR: 1.01, 95%CI: 1.00, 1.02) at baseline and having two or more painful sites were significantly associated with a higher incidence of depression. In contrast, baseline depression was not associated with changes in knee joint symptoms over 24 months.

## Conclusion

Knee OA risk factors and joint symptoms, along with co-existing multi-site pain are associated with the prevalence and development of depression. This suggests that managing common OA risk factors and joint symptoms could be important for prevention and treatment depression in patients with knee OA.

## Background

Osteoarthritis (OA) is a prevalent joint disease, characterised by whole joint structural changes, and is considered as “a serious disease”<sup>1</sup>. OA affects nearly 240 million people throughout the world, and its prevalence is projected to increase as the population ages and obesity rates increase<sup>2</sup>. Joint pain, stiffness and limited function are common joint symptoms of OA, resulting in reduced quality of life and disability that contribute to substantial financial burden for individuals<sup>3</sup>. In addition, OA is associated with comorbidities, including cardiovascular disease, diabetes, hypertension, falls, fractures and depression<sup>1</sup>.

Depression is a major global public-health issue and is projected to be the second leading cause of disease burden by the year 2020<sup>4 5</sup>. A recently systematic review and meta-analysis recently reported that 19.9% of people with OA had depressive symptoms, with a relative risk of depression of 1.17 in those with OA compared to those without<sup>6 7</sup>. However, depression is often under-recognised and under-treated in older adults, particularly in patients with OA<sup>8 9</sup>. Furthermore, concomitant depression in OA patients contributes to increased difficulties in OA management and disease burden<sup>4</sup>. Therefore, the interaction between OA and depression should be taken seriously, and screening, prevention and treatment of depression in OA patients should be considered<sup>10</sup>.

Concomitant depression with OA may be mediated by either biological or behavioural mechanisms with different aetiology and risk factors<sup>4 11</sup>. A better understanding of depression in OA patients is crucial for identifying modifiable risk factors and key areas for intervention<sup>1</sup>. Joint pain, decreased physical performance and increased risks for chronic comorbidities are typical characteristics of OA, which may be associated with depression<sup>9 12 13</sup>; however, the longitudinal relationship between clinical OA characteristics and depression in individuals with OA has been poorly studied. In addition, although the reciprocal relationship between depression severity and pain is established, whether current depression severity predicts changes in joint symptoms overtime has been rarely investigated in knee OA patients<sup>14-16</sup>.

The aims of this study were, therefore, to describe demographic and clinical factors associated with the prevalence and incidence of depression and to explore the temporal relationship between depression and joint symptoms in patients with symptomatic knee OA.

## Methods

### Study design and participants

This study is a post-hoc analysis of a multicenter, randomized, double-blind, placebo-controlled trial, the Vitamin D Effect on Osteoarthritis (VIDEO) study, aimed to evaluate the effect of vitamin D supplementation in patients with symptomatic knee OA and vitamin D deficiency<sup>17</sup>. Participants were allocated to either the treatment or placebo arm at a ratio of 1:1, and received a capsule containing 50,000 IU (1.25 mg) vitamin D<sub>3</sub> (cholecalciferol) or placebo monthly for 24 months<sup>17</sup>. In this current study, both treatment and placebo groups were combined together as a cohort, which adheres to STROBE statement and include a completed STROBE checklist in the supplementary file.

Participants who suffered from symptomatic knee OA (American College of Rheumatology criteria) for at least 6 months in Tasmania and Victoria (Australia) were enrolled<sup>17 18</sup>. Exclusion criteria were detailedly described in the protocol<sup>17</sup>. The important exclusion criteria were participants with the severe radiographic changes (grade 3 on the Altman and Gold atlas) and/or severe knee pain on standing (> 80 mm on a 100-mm VAS)<sup>17</sup>.

## Measurements of depression severity

Depression severity was measured using the patient health questionnaire (PHQ-9) at baseline and 24 month. PHQ-9 is a validly, reliably and commonly used instrument in diagnosing and assessing the severity of depression<sup>19</sup>. It contains nine items with a score range of 0 to 27, with each item being scored from 0 (not at all) to 3 (nearly every day). Based on the generally recommended criterion, a cut-off point of  $\geq 5$  has a sensitivity of 81.5% and a specificity of 80.6% for mild depression and a cut-off point of  $\geq 10$  has a sensitivity of 54.3% and a specificity of 91.1% for moderate or severe depression<sup>20</sup>.

## Anthropometrics and social demographic characteristics

Height and weight were measured to the nearest 0.1 cm and 0.1 kg (with shoes and bulky clothing removed) using electronic scales (Heine S-7307, Heine, New Hampshire, USA) stadiometer (Leicester Height Measure, Invicta Plastics Ltd, Leicester, UK) at baseline. Body mass index (BMI, in  $\text{kg}/\text{m}^2$ ) was calculated<sup>17</sup>. The participants' information of education history, current smoking and concomitant medication usage were collected by the questionnaire at baseline.

## Knee joint symptoms measurement

The Western Ontario and McMaster Universities OA Index (WOMAC) was used to evaluate knee joint symptoms at baseline and 24 month. The index is widely used to assess the joint functional capacity in clinical trials<sup>21</sup>. Three subscales (pain, stiffness, and physical function) and 24 questions (5 related to pain, 2 to stiffness and 17 to physical function) constitutes the index, with scores from 0 (none) to 100 (severe). The sum of three subscales scores is calculated as the total WOMAC score (0-2400).

## Knee joint radiographic measurement

Radiographic OA was assessed at baseline using a standing semi-flexed anterior-posterior radiograph as per the Altman atlas<sup>22</sup>. Radiographs were assessed simultaneously by two observers using the Altman atlas to score osteophytes and joint space narrowing on a four-point scale (0 to 3) at medial tibial, lateral tibial, medial femoral and lateral femoral sites. The presence of radiographic OA was defined as any score of  $\geq 1$  for JSN or osteophytes.

## Physical activity

The pedometer (SW200 Digi-Walker, Yamax Corporation, Tokyo, Japan) was used to assess the physical activity as steps/day at baseline and month 24<sup>17</sup>. All participants were asked to wear pedometers under the guidance from the time they woke up until they went to bed for 7 consecutive days. The number of steps for each day were recorded and mean steps/day was calculated as the average of the days worn at both time points<sup>23</sup>.

## Multi-sites pain

Participants were asked whether they experienced (yes/no) neck, lower back, hands, shoulders and others pain at baseline. The total number of painful locations (range 0 to 5) was categorized into three groups (no pain, one painful site, two or more painful sites).

## **Self-reported medical conditions**

Participants were asked whether they have been diagnosed (yes/no) by a doctor or a nurse with any of the following conditions: depression, angina, high blood pressure, heart attack, stroke, high cholesterol, diabetes, osteoporosis, asthma, bronchitis and emphysema, and whether they had these conditions currently. The total number of current comorbidities, except for depression, was categorized into three groups (no comorbidity, one comorbidity and two or more comorbidities).

## **Data analyses**

Baseline characteristics are described as mean  $\pm$  standard deviation (SD) or numbers of participants (percentage). Univariable and multivariable log-binomial regressions were used to explore risk factors associated with the prevalence of depression at baseline and incidence of depression over time. If the log binomial model failed to converge, it was estimated by using a poisson distribution and robust standard errors. Multivariable models for prevalent depression were adjusted for age, sex, BMI and baseline vitamin D level. Multivariable models for incident depression were adjusted for age, sex, BMI, baseline 25-hydroxyvitamin D level and treatment arms (vitamin D treatment versus placebo). Univariable and multivariable linear regressions were used to examine the temporal relationship between baseline depressive symptoms and change in knee symptoms over 24 months before and after adjustment for age, sex, BMI, baseline 25-hydroxyvitamin D level, treatment arms and baseline WOMAC score. All tests were two-sided and a *P* value of  $< 0.05$  was considered as statistically significant. Stata version 12.0 was used to perform statistical analyses.

## **Results**

### **Baseline characteristics of participants**

Table 1 presents baseline characteristics of the study participants. The mean age of 413 participants was  $63.2 \pm 7.0$  years and mean BMI was  $29.6 \pm 5.0$ . Of them, 208 (50.4%) participants were female and 209 (50.6%) were allocated to the treatment group. At baseline, 296 (74.6%) participants were identified as not suffering from depression, 70 (17.6%) were identified as suffering from mild depression, and 31 (7.8%) were identified as suffering from moderate to severe depression. The prevalence of any depression in this study was 25.4% (according to the PHQ-9), 5.8% participants had self-reported depression and 4.3% used anti-depressant medications.

Table 1  
Baseline characteristics of participants (N = 413)

	Mean/ Numbers	SD/ Percentage
Age (years)	63.2	7.0
Female sex (n, %)	208	50.4
Body mass index (kg/m <sup>2</sup> )	29.6	5.0
Serum 25-(OH)D levels (nmol/L)	43.8	12.2
PHQ-9 score		
0–4	296	74.6
5–9	70	17.6
≥ 10	31	7.8
Anti-depressant medication use (n, %)	17	4.3
Physical activity, (1000 step/day)	7.4	3.4
Education		
School only (n, %)	51	12.5
High school (n, %)	101	24.7
University or higher (n, %)	257	62.8
Radiographic osteoarthritis (n, %)	339	96.0
WOMAC score		
Pain (0-500)	136.3	86.1
Function (0-1700)	478.0	305.8
Stiffness (0-200)	57.4	16.6
Multi-site joint pain, (n, %)		
No pain	252	61.0
One site	136	32.9
More than one site	25	6.1
Comorbidity, (n, %)		
No comorbidity	170	41.2

PHQ-9, patient health questionnaire depression scale; WOMAC, Western Ontario and McMaster Universities Arthritis Index.

	Mean/ Numbers	SD/ Percentage
One comorbidity	229	55.5
More than one comorbidity	14	3.4
PHQ-9, patient health questionnaire depression scale; WOMAC, Western Ontario and McMaster Universities Arthritis Index.		

## Factors associated with the prevalence of depression

As shown in Table 2, being female, and having a higher BMI, greater scores of WOMAC pain (Fig. 1A), WOMAC function (Fig. 1B) and WOMAC stiffness, a lower education level, and more than one comorbidity were significantly associated with a higher prevalence of depression in univariable analyses. After adjustment for age, sex, BMI and baseline 25-(OH)D level, the associations persisted except for female sex, which was no longer statistically significant. Having two or more sites of pain was significantly associated with a higher prevalence of depression in multivariable analyses. Age and radiographic OA were not significantly associated with the prevalence of depression in either univariable or multivariable analysis. Results were similar, when self-reported depression was used as the outcome or if the analyses were adjusted for anti-depressant medication use (data not shown).

Table 2  
Factors associated with the prevalence of mild to severe depression at baseline

	Univariable	Multivariable*
	PR (95% CI)	PR (95% CI)
Age (years)	0.99 (0.98, 1.01)	0.96 (0.94, 0.99)
Female sex (n, %)	<b>1.55 (1.10, 2.18)</b>	1.38 (0.98, 1.96)
BMI (kg/m <sup>2</sup> )	<b>1.06 (1.03, 1.09)</b>	<b>1.05 (1.02, 1.08)</b>
Physical activity, (1000 steps/day)	0.96 (0.92, 1.01)	0.96 (0.90, 1.03)
<b>Education</b>		
School only (n, %)	<i>Reference</i>	<i>Reference</i>
High school (n, %)	0.63 (0.40, 1.00)	<b>0.61 (0.40, 0.95)</b>
University or higher (n, %)	<b>0.47 (0.30, 0.73)</b>	<b>0.50 (0.34, 0.74)</b>
Radiographic osteoarthritis (n, %)	0.98 (0.94, 1.02)	0.98 (0.94, 1.02)
<b>WOMAC score/ 10 unit</b>		
Pain (0–50)	<b>1.04 (1.03, 1.07)</b>	<b>1.05 (1.03, 1.07)</b>
Function (0-170)	<b>1.02 (1.01, 1.02)</b>	<b>1.02 (1.01, 1.02)</b>
Stiffness (0–20)	<b>1.07 (1.04, 1.11)</b>	<b>1.05 (1.02, 1.09)</b>
Multi-site joint pain, (n, %)		
No pain	<i>Reference</i>	<i>Reference</i>
One site	1.21 (0.85, 1.74)	1.06 (0.75, 1.51)
More than one site	1.64 (0.93, 2.88)	<b>1.73 (1.01, 2.98)</b>
Comorbidity, (n, %)		
No comorbidity	<i>Reference</i>	<i>Reference</i>
One comorbidity	1.08 (0.75, 1.55)	1.14 (0.80, 1.65)
More than one comorbidity	<b>2.13 (1.18, 3.86)</b>	<b>1.98 (1.03, 3.80)</b>
* All multivariable analyses were adjusted for age, sex, BMI and baseline 25-(OH)D level, except for age (adjusted for sex, BMI and baseline 25-(OH)D level), sex (adjusted for age, BMI and baseline 25-(OH)D level) and BMI (adjusted for age, sex and baseline 25-(OH)D level).		
Mild to severe depression was defined as PHQ-9 scores $\geq 5$ .		

## Factors associated with incident depression

340 participants completed the follow-up. 28 out of 249 participants (11.2%) without depression at baseline had incident mild to severe depression at 24 months. Table 3 shows the factors associated with incident depression. Being female and having a higher WOMAC pain (Fig. 1C) and WOMAC function (Fig. 1D) score were significantly associated with greater incident depression over 24 months in univariable and multivariable analyses. Having two or more painful sites was significantly associated with greater incident depression over 24 months in the multivariable analyses. In a sensitivity analysis further adjusting for anti-depressant medication, the results were largely unchanged (data not shown). In contrast, there were no significant associations between age, BMI, physical activity, education, radiographic OA, WOMAC stiffness, comorbidity and incident depression.

Table 3

Factors associated with the incidence of mild to severe depression at 24 months amongst participants without depression at baseline

	<b>Univariable</b>	<b>Multivariable*</b>
	<b>RR (95% CI)</b>	<b>RR (95% CI)</b>
Age (years)	0.99 (0.94, 1.04)	1.00 (0.96, 1.05)
Female sex (n, %)	<b>2.23 (1.06, 4.66)</b>	<b>2.33 (1.09, 4.95)</b>
Body mass index (kg/m <sup>2</sup> )	0.98 (0.91, 1.06)	0.98 (0.91, 1.06)
Physical activity, (steps/day)	1.01 (0.90, 1.13)	0.99 (0.87, 1.12)
<b>Education</b>		
School only (n, %)	<i>Reference</i>	<i>Reference</i>
High school (n, %)	0.86 (0.24, 3.10)	0.81 (0.22, 2.94)
University or higher (n, %)	0.89 (0.28, 2.82)	0.89 (0.28, 2.84)
Radiographic osteoarthritis (n, %)	0.92 (0.84, 1.01)	0.93 (0.85, 1.02)
<b>WOMAC score/ 10 unit</b>		
Pain (0–50)	<b>1.04 (1.00, 1.08)</b>	<b>1.04 (1.00, 1.08)</b>
Function (0-170)	<b>1.01 (1.00, 1.02)</b>	<b>1.01 (1.00, 1.02)</b>
Stiffness (0–20)	1.01 (0.93, 1.11)	1.01 (0.93, 1.10)
Multi-site joint pain, (n, %)		
No pain	<i>Reference</i>	<i>Reference</i>
One site	1.30 (0.61, 2.75)	1.13 (0.53, 2.42)
More than one site	2.17 (0.69, 6.80)	<b>3.63 (1.04, 12.7)</b>
Comorbidity, (n, %)		
No comorbidity	<i>Reference</i>	<i>Reference</i>
One comorbidity	0.93 (0.45, 1.91)	1.01 (0.48, 2.14)
More than one comorbidity	1.12 (0.16, 7.68)	0.97 (0.14, 6.87)
* All multivariable analyses were adjusted for age, sex, BMI and baseline 25-(OH)D level, except for age (adjusted for sex, BMI and baseline 25-(OH)D level), sex (adjusted for age, BMI and baseline 25-(OH)D level) and BMI (adjusted for age, sex and baseline 25-(OH)D level).		
Mild to severe depression was defined as PHQ-9 scores $\geq$ 5.		

# Temporal relationship between baseline depression and changes in joint symptoms overtime

Table 4 describes the longitudinal association of baseline depression with changes in knee joint symptoms over 24 months. Although participants with mild to severe depression had greater decreases in WOMAC symptoms compared to participants without depression at baseline in the univariable analyses, the significant associations disappeared in the multivariable analyses. In addition, the results were consistent when either self-reported depression at baseline was used as the exposure or if the analyses were adjusted for anti-depressant medication use (data not shown).

Table 4

The association between depression severity at baseline and change in joint symptom over 24 months

	Univariable $\beta$ (95% CI)	Multivariable $\beta$ (95% CI)
<b>WOMAC score</b>		
Pain (0-500) †		
No depression	<i>Reference</i>	<i>Reference</i>
Mild depression	<b>-35.8 (-63.7, -7.9)</b>	-12.4 (-36.7, 11.8)
Moderate to severe depression	<b>-100.3 (-143.1, -57.4)</b>	-32.0 (-72.2, 8.2)
Function (0-1700) ‡		
No depression	<i>Reference</i>	<i>Reference</i>
Mild depression	<b>-139.9 (-222.2, -57.7)</b>	-67.8 (-145.4, 9.7)
Moderate to severe depression	<b>-225.4 (-357.5, -93.2)</b>	-90.3 (-220.3, 39.7)
Stiffness (0-200) §		
No depression	<i>Reference</i>	<i>Reference</i>
Mild depression	<b>-13.2 (-26.0, -0.5)</b>	-5.2 (-16.5, 6.1)
Moderate to severe depression	<b>-29.4 (-49.0, -9.8)</b>	-11.8 (-30.0, 6.5)
† Multivariable analysis was adjusted for age, sex, BMI, baseline 25-(OH)D level, treatment arm and baseline WOMAC pain score.		
‡ Multivariable analysis was adjusted for age, sex, BMI, baseline 25-(OH)D level, treatment arm and baseline WOMAC function score.		
§ Multivariable analysis was adjusted for age, sex, BMI, baseline 25-(OH)D level, treatment arm and baseline WOMAC stiffness score.		

## Discussion

This study investigated the temporal relationships between demographic and OA clinical factors, joint symptoms and depression in patients with symptomatic knee OA. Depression was common in this population with a prevalence of 25.4% and incidence of 11.2% over 24 months. Common OA risk factors such as higher BMI, lower education level and having two or more comorbidities were associated with prevalent depression and being female was associated with incident depression in knee OA patients. Higher levels of knee pain and physical dysfunction and having multi-site pain were associated with increased risks of both prevalent and incident depression. In contrast, baseline depression severity did not predict changes in OA symptoms. These findings provide empirical evidence that management of common OA risk factors, chronic pain and joint dysfunction may be beneficial for preventing and managing depression in knee OA patients.

Numerous studies have explored the demographic factors associated with depression in elderly populations. Female sex, lower education levels and the biological risks including endocrine and inflammatory factors are potential risk factors for depression in the elderly<sup>24</sup>. However, only a few studies have been conducted in individuals with OA, and most did not assess longitudinal relationships. A cross-sectional study reported that fewer social contacts, increased BMI, perceived pain and limited physical activity were associated with depression severity in 1021 patients with knee OA<sup>13</sup>. In our current study, we reported similar results and reported that, cross-sectionally, higher BMI, lower education level and having two or more comorbidities were associated with prevalent depression.

Obesity, female sex and a lower education level are known as risk factors for both OA and depression. Therefore, the high prevalence depression in OA individuals may be in part attributed to shared risk factors. Taking higher BMI for example, higher BMI, indicating overweight or obesity, is a well-known risk factor of OA and also can increase vulnerability to depression directly and indirectly through complex mechanisms<sup>25 26</sup>. Obesity causes a high prevalence<sup>25</sup> of OA, which may be related to combined effects from biomechanical, inflammatory and metabolic factors. In addition, obesity can induce poor self-image, low self-esteem and social isolation, which are well-known contributors to depression. It also can activate inflammatory pathways, involving hypothalamic-pituitary-adrenal axis dysregulation, which are associated with increased risk of depression through biological and psychological pathways<sup>25</sup>. Obesity and lower levels of education are modifiable factors; therefore, management of obesity and improvement of education level may prevent depression and should have beneficial effects in patients with knee OA. Additionally, female sex predicted incident depression over 24 months in knee OA patients. Hence, it is important for clinicians to screen for, and try to prevent and treat depression, especially in female patients with knee OA.

Joint pain and dysfunction, multisite pain and comorbidities are clinical characteristics of OA. Multisite pain, joint pain and joint function limitation are common in musculoskeletal conditions, and have been linked to depression in previous studies<sup>27</sup>. Individuals who experienced chronic pain and physical activity limitation are at an increased risk of depression<sup>28 29</sup>. In OA patients, joint pain severity and dysfunction

were associated with depression severity cross-sectionally and longitudinally<sup>30-35</sup>. Knee OA patients with greater pain associated with higher risk of depression at baseline and slow gait speed may represent an important risk factor for worsening depressive symptoms over time<sup>33 35</sup>. In our study, although we used a different method to assess depression severity, we found similar results. Individuals who experienced multi-site pain, more severe knee pain and joint dysfunction, and had more than one comorbidity were at a higher risk of prevalent depression cross-sectionally in knee OA patients. Over 24 months, multi-site pain, knee pain and dysfunction were associated with increased incidence of depression over 24 months, suggesting a potentially causal relationship. These supported the notion that management of pain, joint dysfunction and other comorbidities may help to improve depression in knee OA patients<sup>15 36</sup>.

Depression severity is dynamic, changing over time, and prior depressive illness modifies the experience of currently depressed mood<sup>37</sup>. The reciprocal relationship between depression severity and pain severity has been well established, but whether current depression severity has causal effects on severity of joint symptoms overtime has been rarely investigated<sup>14 16</sup>. Kurt et al have reported that change in pain severity over 3 months predicted subsequent depression severity, and vice versa, change in depression severity over 3 months predicted subsequent pain severity over 12 months in patients with persistent back, hip and knee pain<sup>14</sup>. In knee OA patient, we only found higher levels of knee joint symptoms and having multi-site pain at baseline were associated with increased risks of both prevalent and incident depression, while baseline depression severity did not predict knee joint symptomatic progression over two years. There was one study have explored the causal cumulative effect between depressive symptoms and knee pain among patients with knee radiographic OA. Rathbun reported the causal effect of pain severity significantly increases with the persistence of depressed mood, but depressive symptoms on OA knee pain does not change over time, which was similar with this current study<sup>16</sup>. Our findings suggest the potentially cause-effect relationship is from knee joint pain and physical dysfunction to depression, rather than from depression to knee symptoms, in patients with knee OA.

This study has some potential limitations. It was a post-hoc analysis of a randomized controlled trial which was primarily designed to examine vitamin D supplementation on knee OA outcomes. Nevertheless, the findings from this study were plausible as we found that vitamin D supplementation reduced visual analog scale knee pain, improved physical function and decreased depressive symptoms<sup>38 39</sup>. The effects on depressive symptoms may be mediated through the effects on knee pain and physical function. In addition, 18% participants did not complete the 24 months follow-up, and loss of follow-up bias may be present; however, the retention rate in this trial was high, and there were no significant differences in the baseline characteristics between those who completed and who did not complete the trial. This suggests a minimal loss of follow-up bias in our study. Furthermore, we defined depression using the patient health questionnaire, which was developed for depression diagnostic, severity measures and assessment of depression outcome changes over time. It may lead to misclassification of depression; however, when we used the self-reported depression as the outcome or exposure and anti-depressant medication as a covariate and the results were largely unchanged.

## Conclusions

Knee OA risk factors and joint symptoms, along with co-existing multi-site pain are associated with the prevalence and development of depression. This suggests that managing common OA risk factors and joint symptoms could be important for prevention and treatment depression in patients with knee OA.

## List Of Abbreviations

<b>BMI</b>	<b>Body Mass Index</b>
OA	Osteoarthritis
PHQ-9	Patient Health Questionnaire
SD	Standard Deviation
VAS	Visual Analogue Scale
VIDEO	Vitamin D Effect on Osteoarthritis Study
WOMAC	Western Ontario and McMaster Universities Osteoarthritis Index

## Declarations

### Ethics approval and consent to participate:

The study was approved by the Tasmania Health and Human Medical Research Ethics Committee (reference number H1040) and Monash University Human Research Ethics Committee (reference number CF10/1182-2010000616). Statement of consent: All included participants were provided both written and verbal information. Informed written consent was obtained from all decision-capable participants.

#### Consent for publication:

*Not applicable.*

#### Availability of data and materials:

The data that support the findings of this study are available from University of Tasmania Database, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are available from the corresponding author upon reasonable request and with permission of University of Tasmania Database.

#### Competing interests:

Authors Changhai Ding, Flavia Cicuttini, and Anita E Wluka are the member of the editor board of this journal.

## Funding:

The study presents independent research funded by the Australian National Health and Medical Research Council Grant (Project Code 605501). The study design, methods, participants recruitment, data collection and analysis, and manuscript preparation were independent on the funder.

## Authors' contribution:

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. SZ had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. SZ and CD designed the study, collected data, carried out data analyses, interpreted the results and drafted the manuscript. LT, FC, WH, ZZ, BA, AW, TW, TM, DA, LB and GJ were involved in collecting the data, helping the data analyses, interpreting the results and revising the manuscript.

## Acknowledgement:

We specially thank the participants who made this study possible, and we gratefully acknowledge the role of Vitamin D Effect on Osteoarthritis Study staff and volunteers in collecting the data. We thank the research assistants Jodi Barling, Kay Nguo, Judy Hankin and Alice Noon who were involved in the coordination of this study.

## References





1. OARSI. Osteoarthritis: A Serious Disease. Osteoarthritis Research Society International, 2016:1-103.
2. Nelson AE. Osteoarthritis year in review 2017: clinical. *Osteoarthr Cartilage* 2018;26(3):319-25. doi: 10.1016/j.joca.2017.11.014 [published Online First: 2017/12/13]
3. Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. *Ann Rheum Dis* 2014;73(7):1323-30. doi: 10.1136/annrheumdis-2013-204763 [published Online First: 2014/02/21]
4. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. *Lancet* 2007;370(9590):851-58. doi: 10.1016/S0140-6736(07)61415-9
5. Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ* 2011;343:683-87. doi: 10.1136/bmj.d5219 [published Online First: 2011/10/01]

6. Stubbs B, Aluko Y, Myint PK, et al. Prevalence of depressive symptoms and anxiety in osteoarthritis: a systematic review and meta-analysis. *Age Ageing* 2016;45(2):228-35. doi: 10.1093/ageing/afw001
7. Kessler RC, Berglund P, Demler O, et al. The Epidemiology of Major Depressive Disorder: Results From the National Comorbidity Survey Replication (NCS-R). *JAMA* 2003;289(23):11.
8. Gleicher Y, Croxford R, Hochman J, et al. A prospective study of mental health care for comorbid depressed mood in older adults with painful osteoarthritis. *Bmc Psychiatry* 2011;11(1):147. doi: 10.1186/1471-244X-11-147 [published Online First: 2011/09/14]
9. Fiske A, Wetherell JL, Gatz M. Depression in older adults. *Annu Rev Clin Psycho* 2009;5:363-89. doi: 10.1146/annurev.clinpsy.032408.153621 [published Online First: 2009/03/31]
10. Marks R. Comorbid depression and anxiety impact hip osteoarthritis disability. *Disabil Health J* 2009;2(1):27-35. doi: 10.1016/j.dhjo.2008.10.001
11. Simon GE. Treating depression in patients with chronic disease. *Western Journal of Medicine* 2001;175(5):292-93.
12. Zambon S, Siviero P, Denkinger M, et al. Role of Osteoarthritis, Comorbidity, and Pain in Determining Functional Limitations in Older Populations: European Project on Osteoarthritis. *Arthritis Care Res* 2016;68(6):801-10. doi: 10.1002/acr.22755 [published Online First: 2015/10/17]
13. Rosemann T, Backenstrass M, Joest K, et al. Predictors of depression in a sample of 1,021 primary care patients with osteoarthritis. *Arthritis Rheum* 2007;57(3):415-22. doi: 10.1002/art.22624
14. Kroenke K, Wu J, Bair MJ, et al. Reciprocal relationship between pain and depression: a 12-month longitudinal analysis in primary care. *J Pain* 2011;12(9):964-73. doi: 10.1016/j.jpain.2011.03.003 [published Online First: 2011/06/18]
15. Hawker GA, Gignac MA, Badley E, et al. A longitudinal study to explain the pain-depression link in older adults with osteoarthritis. *Arthritis Care Res* 2011;63(10):1382-90. doi: 10.1002/acr.20298
16. Rathbun AM, Stuart EA, Shardell M, et al. Dynamic Effects of Depressive Symptoms on Osteoarthritis Knee Pain. *Arthritis Care Res* 2018;70(1):80-88. doi: 10.1002/acr.23239 [published Online First: 2017/03/21]
17. Cao Y, Jones G, Cicuttini F, et al. Vitamin D supplementation in the management of knee osteoarthritis: study protocol for a randomized controlled trial. *Trials* 2012;13:131. doi: 10.1186/1745-6215-13-131
18. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. *Arthritis Rheum* 1986;29(8):1039-49.
19. Lowe B, Unutzer J, Callahan CM, et al. Monitoring depression treatment outcomes with the patient health questionnaire-9. *Med Care* 2004;42(12):1194-201.
20. Stafford L, Berk M, Jackson HJ. Validity of the Hospital Anxiety and Depression Scale and Patient Health Questionnaire-9 to screen for depression in patients with coronary artery disease. *Gen Hosp Psychiat* 2007;29(5):417-24. doi: 10.1016/j.genhosppsy.2007.06.005

21. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. *J Rheumatol* 1988;15(12):1833-40.
22. Altman RD, Gold GE. Atlas of individual radiographic features in osteoarthritis, revised. *Osteoarthr Cartilage* 2007;15 Suppl A:A1-56. doi: 10.1016/j.joca.2006.11.009 [published Online First: 2007/02/27]
23. Doré DA, Winzenberg TM, Ding C, et al. The association between objectively measured physical activity and knee structural change using MRI. *Ann Rheum Dis* 2013;72(7):1170-75. doi: 10.1136/annrheumdis-2012-201691
24. Sozeri-Varma G. Depression in the elderly: clinical features and risk factors. *Aging Dis* 2012;3(3):465-71. [published Online First: 2012/12/20]
25. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. *Arch Gen Psychiat* 2010;67(3):220-9. doi: 10.1001/archgenpsychiatry.2010.2 [published Online First: 2010/03/03]
26. Plotnikoff R, Karunamuni N, Lytvyak E, et al. Osteoarthritis prevalence and modifiable factors: a population study. *BMC Public Health* 2015;15:1195. doi: 10.1186/s12889-015-2529-0 [published Online First: 2015/12/02]
27. Zis P, Daskalaki A, Bountouni I, et al. Depression and chronic pain in the elderly: links and management challenges. *Clin Interv Aging* 2017;12:709-20. doi: 10.2147/CIA.S113576 [published Online First: 2017/05/04]
28. McCarthy LH, Bigal ME, Katz M, et al. Chronic pain and obesity in elderly people: results from the Einstein aging study. *J Am Geriatr Soc* 2009;57(1):115-9. doi: 10.1111/j.1532-5415.2008.02089.x [published Online First: 2008/12/05]
29. Bauer H, Emeny RT, Baumert J, et al. Resilience moderates the association between chronic pain and depressive symptoms in the elderly. *European journal of pain (London, England)* 2016;20(8):1253-65. doi: 10.1002/ejp.850 [published Online First: 2016/02/26]
30. Rosemann T, Laux G, Szecsenyi J. Osteoarthritis: quality of life, comorbidities, medication and health service utilization assessed in a large sample of primary care patients. *J Orthop Surg Res* 2007;2(12):1-9. doi: 10.1186/1749-799x-2-12 [published Online First: 2007/07/03]
31. Rosemann T, Laux G, Szecsenyi J, et al. Pain and osteoarthritis in primary care: factors associated with pain perception in a sample of 1,021 patients. *Pain Med* 2008;9(7):903-10. doi: 10.1111/j.1526-4637.2008.00498.x [published Online First: 2008/08/16]
32. Holla JFM, van der Leeden M, Knol DL, et al. The association of body-mass index and depressed mood with knee pain and activity limitations in knee osteoarthritis: results from the Amsterdam osteoarthritis cohort. *BMC Musculoskel Dis* 2013;14(1):296-12. doi: 10.1186/1471-2474-14-296 [published Online First: 2013/10/18]
33. Collins JE, Katz JN, Dervan EE, et al. Trajectories and risk profiles of pain in persons with radiographic, symptomatic knee osteoarthritis: data from the osteoarthritis initiative. *Osteoarthr*

- Cartilage* 2014;22(5):622-30. doi: 10.1016/j.joca.2014.03.009 [published Online First: 2014/03/26]
34. Machado GP, Gignac MA, Badley EM. Participation restrictions among older adults with osteoarthritis: a mediated model of physical symptoms, activity limitations, and depression. *Arthritis Rheum* 2008;59(1):129-35. doi: 10.1002/art.23259 [published Online First: 2008/01/01]
35. White DK, Neogi T, Zhang Y, et al. Association of Slow Gait Speed With Trajectories of Worsening Depressive Symptoms in Knee Osteoarthritis: An Observational Study. *Arthritis Care Res* 2017;69(2):209-15. doi: 10.1002/acr.22928 [published Online First: 2016/05/10]
36. Kroenke K, Shen J, Oxman TE, et al. Impact of pain on the outcomes of depression treatment: results from the RESPECT trial. *Pain* 2008;134(1-2):209-15. doi: 10.1016/j.pain.2007.09.021
37. Monroe SM, Slavich GM, Gotlib IH. Life stress and family history for depression: the moderating role of past depressive episodes. *J Psychiatr Res* 2014;49:90-95. doi: 10.1016/j.jpsychires.2013.11.005 [published Online First: 2013/12/07]
38. Jin X, Jones G, Cicuttini F, et al. Effect of Vitamin D Supplementation on Tibial Cartilage Volume and Knee Pain Among Patients With Symptomatic Knee Osteoarthritis. *JAMA* 2016;315(10):1005-13. doi: 10.1001/jama.2016.1961
39. Zheng S, Tu L, Cicuttini F, et al. Effect of Vitamin D Supplementation on Depressive Symptoms in Patients With Knee Osteoarthritis. *J Am Med Dir Assoc* 2019;20(12):1634-40 e1. doi: 10.1016/j.jamda.2018.09.006 [published Online First: 2018/11/08]

## Figures



**Figure 1**

Associations of baseline WOMAC pain (0-500) and WOMAC function (0-1700) tertiles with the prevalence (A, B) and incidence (C, D) of depression in patients with knee OA.